While neoadjuvant immunotherapy and chemoradiotherapy can improve rectal cancer patient outcomes, there is a need to better identify those who will respond well. Here, the authors present a single-arm phase II trial reporting the efficacy and safety of neoadjuvant chemoradiotherapy and sintilimab (anti-PD-1) in patients with locally advanced rectal cancer with proficient mismatch repair and intermediate/high Immunoscores.
- Xiaobin Zheng
- Huashan Liu
- Liang Kang
